TG Therapeutics Inc TGTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:54 PM EST
42.02quote price arrow down-0.71 (-1.66%)
Volume
1,282,241
52 week range
6.34 - 56.74

...

Loading . . .

KEY STATS

  • Open42.95
  • Day High43.97
  • Day Low40.83
  • Prev Close42.73
  • 52 Week High56.74
  • 52 Week High Date01/13/21
  • 52 Week Low6.34
  • 52 Week Low Date03/18/20
  • Market Cap5.908B
  • Shares Out140.59M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta2.21
  • 1 Year % Change210.66

RATIOS/PROFITABILITY

  • EPS (TTM)-2.10
  • P/E (TTM)-20.05
  • Fwd P/E (NTM)-21.41
  • EBITDA (MRQ)-224.64M
  • ROE (MRQ)-318.55%
  • Revenue (MRQ)150,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-151,799.30%
  • Debt To Equity (MRQ)17.66%

EVENTS

  • Earnings Date05/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest TG Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is...
Michael Weiss J.D.
Chairman
Sean Power CPA
Chief Financial Officer
Kelly Ross
Chief Technology Officer
Address
2 Gansevoort St Fl 9
New York, NY
10014-1667
United States